Silencing of long non-coding RNA H19 downregulates CTCF to protect against atherosclerosis by upregulating PKD1

Yongyao Yang1, Feng Tang1, Fang Wei1

  • 1Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang 550002, P. R. China.

Aging
|November 24, 2019
PubMed

Insights

Long non-coding RNA H19 recruits CTCF to suppress PKD1, promoting atherosclerosis. Silencing H19 inhibits plaque formation and angiogenesis, offering therapeutic potential for atherosclerosis.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • RNA Biology

Background:

  • Atherosclerosis involves complex molecular interactions contributing to vulnerable plaque formation and angiogenesis.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized as key regulators in cardiovascular diseases.

Purpose of the Study:

  • To elucidate the interaction between lncRNA H19, CTCF, and PKD1 in atherosclerosis.
  • To investigate the regulatory role of this axis in vulnerable plaque formation and angiogenesis.

Main Methods:

  • Atherosclerosis mouse model established using ApoE knockout mice.
  • Gain- and loss-of-function approaches employed to manipulate H19 and CTCF expression.
  • Analysis of gene expression (MMP-2, VEGF, p53, TIMP-1) and plaque characteristics.

Main Results:

  • H19 was upregulated in atherosclerotic mouse aortas.
  • H19 silencing reduced plaque formation and angiogenesis, altering MMP-2, VEGF, p53, and TIMP-1 levels.
  • H19 recruited CTCF to suppress PKD1, promoting atherosclerosis progression.

Conclusions:

  • H19-CTCF interaction downregulates PKD1, driving vulnerable plaque formation and angiogenesis.
  • Targeting the H19/CTCF/PKD1 pathway may offer a novel therapeutic strategy for atherosclerosis.